Article
Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer.
Thyroid : official journal of the American Thyroid Association - 1 Oct 2023
Gunda Viswanath, Ghosh Chandrayee, Hu Jiangnan, Zhang Lisa, Zhang Ya Qin, Shen Min, Kebebew Electron
Abstract excerpt
Background: Anaplastic thyroid cancer (ATC) is uniformly lethal. BRAFV600E mutation is present in 45% of patients with ATC. Targeted therapy with combined BRAF and MEK inhibition in BRAFV600E-mutant ATC can be effective, but acquired resistance is common because this combination targets the same pathway. Drug matrix screening, in BRAFV600E ATC cells, of highly active compounds in combination with BRAF inhibition...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.